← All trials
NCT06520176
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Jul 25, 2024
- Last posted
- Jul 25, 2024
- Enrollment
- 99
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ningbo UniversityLead sponsor
- Wenzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- The Central Hospital of Lishui CityCollaborator
- Shaoxing Second HospitalCollaborator
- Jinhua People's HospitalCollaborator
- Dongyang People's HospitalCollaborator
- Ningbo Medical Center Lihuili Eastern HospitalCollaborator
- Nanchang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Jinhua Central HospitalCollaborator
- Shaoxing People's HospitalCollaborator
- Zhejiang UniversityCollaborator
- Huizhou People's Central HospitalCollaborator
- Ningbo UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.